Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
=================================================================================================================================================================

* Lu Xie
* Jie Xu
* Xin Sun
* Wei Guo
* Jin Gu
* Kuisheng Liu
* Bingxin Zheng
* Tingting Ren
* Yi Huang
* Xiaodong Tang
* Taiqiang Yan
* Rongli Yang
* Kunkun Sun
* Danhua Shen
* Yuan Li